<SEC-DOCUMENT>0001437749-25-023646.txt : 20250728
<SEC-HEADER>0001437749-25-023646.hdr.sgml : 20250728
<ACCEPTANCE-DATETIME>20250728160843
ACCESSION NUMBER:		0001437749-25-023646
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250728
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250728
DATE AS OF CHANGE:		20250728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		251155646

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crvo20250728_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:crvo="http://www.crvo.com/20250728"><head>
	<title>crvo20250728_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 7/28/2025 3:01:54 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20258K" name="dei:AmendmentFlag" id="ixv-291">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20258K" name="dei:EntityCentralIndexKey" id="ixv-292">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="crvo-20250728.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20258K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-07-28</xbrli:startDate>
<xbrli:endDate>2025-07-28</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20258K" name="dei:DocumentType" id="ixv-302">8-K</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-303">July 28, 2025</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityRegistrantName" id="ixv-304">CervoMed Inc.</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-305">Delaware</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: top; width: 34%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityFileNumber" id="ixv-306">001-37942</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityTaxIdentificationNumber" id="ixv-307">30-0645032</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></div>
			</td>
			<td style="vertical-align: top; width: 34%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></div>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine1" id="ixv-308">20 Park Plaza, Suite 424</ix:nonNumeric></b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressCityOrTown" id="ixv-309">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-310">Massachusetts</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align: bottom; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressPostalZipCode" id="ixv-311">02116</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></div>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20258K" name="dei:CityAreaCode" id="ixv-312">617</ix:nonNumeric>) <ix:nonNumeric contextRef="d20258K" name="dei:LocalPhoneNumber" id="ixv-313">744-4400</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">___________________________</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-314">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-315">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-316">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-317">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:Security12bTitle" id="ixv-318">Common Stock</ix:nonNumeric>, $0.001 par value</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:TradingSymbol" id="ixv-319">CRVO</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-320">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-321">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Regulation FD Disclosure</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Press Release</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 28, 2025, CervoMed Inc. (the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) issued a press release announcing 32-week data from the extension phase (the &#8220;Extension Phase&#8221;) of the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (&#8220;RewinD-LB&#8221;). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Presentation</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including Week 32 results from the Extension Phase of RewinD-LB, has been made available on our website, www.cervomed.com, under the heading, &#8220;Investors &#8211; Events and Presentations.&#8221; Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the presentation is summary information that is intended to be considered in the context of the Company&#8217;s filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">--</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information in this Item 7.01 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 8.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Other Events </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information set forth in the first paragraph and the information under the headings, &#8220;New Data: 32-Week Results from the Extension Phase of the Phase 2b RewinD-LB Trial,&#8221; &#8220;New Data: Reduction in Plasma Levels of Glial Fibrillary Acidic Protein at Week 32 of Extension Phase,&#8221; &#8220;Previously Presented 16-Week Extension Phase Data,&#8221; and &#8220;Old and New Capsules Have Similar Overall Safety and Tolerability Profile During Extension Phase,&#8221; of the Company&#8217;s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current&#160;Report&#160;on&#160;Form&#160;8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 9.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Financial Statements and Exhibits</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><i>Exhibits</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following exhibit relating to Item 7.01 is furnished and not filed:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
			<td style="vertical-align: middle; width: 92%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_844372.htm" style="-sec-extract:exhibit;">Press Release, issued July 28, 2025.</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 50%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: July 28, 2025</div>
			</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CervoMed Inc.</b></div>
			</td>
			<td style="vertical-align: middle; width: 12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 3%;">&#160;</td>
			<td style="vertical-align: middle; width: 35%;">&#160;</td>
			<td style="vertical-align: middle; width: 12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ William Elder</div>
			</td>
			<td style="vertical-align: middle; width: 12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:</div>
			</td>
			<td style="vertical-align: middle; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William Elder</div>
			</td>
			<td style="vertical-align: middle; width: 12%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</div>
			</td>
			<td style="vertical-align: middle; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer &amp; General Counsel</div>
			</td>
			<td style="vertical-align: middle; width: 12%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_844372.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_844372.htm</title>

	<!-- Generated by ThunderDome Portal - 7/28/2025 2:54:16 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="image1.jpg" src="image1.jpg"></div>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod</b>&#8217;<b>s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 &lt; 2.2 pg/mL at screening)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Conference call and webcast today at</i>&nbsp;<i>8:00 AM ET</i>&nbsp;<i>today to discuss results</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> July 28, 2025 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial showing that oral neflamapimod continued to demonstrate slowing of disease progression and demonstrated an effect on a plasma marker of neurodegeneration in patients with DLB. The disease progression analyses were featured in two presentations during the Alzheimer&#8217;s Association&#174; International Congress 2025 (AAIC) on Sunday, July 27<sup style="vertical-align:top;line-height:120%;">th</sup>, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;We are thrilled by these unprecedented data demonstrating a 54% reduction in risk of clinically significant worsening on the CDR-SB over 32&#8239;weeks of treatment, improving to 64% when applying the more stringent ptau181 threshold to define DLB without Alzheimer&#8217;s Disease (AD) co&#8209;pathology &#8211; underscoring neflamapimod&#8217;s potential to have a powerful impact on CDR&#8209;SB, a gold standard measure of clinical progression in dementia trials,&#8221; said John&nbsp;Alam, MD, Co&#8209;Principal Investigator of the RewinD&#8209;LB trial and CEO of CervoMed. &#8220;Combined with the positive effects on a robust blood-based biomarker of the underlying neurodegenerative process, these results bolster our confidence as we progress towards initiating a Phase 3 trial and prepare to meet with the U.S. Food and Drug Administration in the fourth quarter of 2025 to align on the trial design. We remain deeply committed to delivering a meaningful treatment option for underserved DLB patients and their families.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;These new data are potentially transformative with respect to our understanding of the potential of neflamapimod in the treatment of DLB,&#8221; said Lawrence S. Honig, MD, PhD, Professor of Neurology at Columbia University Irving Medical Center and the investigator who presented the results AAIC. "Reducing the risk of a 1.5&#8209;point worsening over 32 weeks on the CDR&#8209;SB by more than 50% would likely represent a clinically meaningful slowing of clinical progression at a level that patients and caregivers would notice in day&#8209;to&#8209;day function. This level of effect, if confirmed in a Phase 3 pivotal trial, would be an important advance in the unmet treatment needs of patients with DLB, the second most common dementia, which is a challenging disease, due to its involvement of both movement and cognition, and due to the lack of effective current treatments.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="image1.jpg" src="image1.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>New Data: 32-Week Results from the Extension Phase of the Phase 2b RewinD-LB Trial<sup style="vertical-align:top;line-height:120%;">1</sup></u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">In the RewinD-LB trial, an older batch of neflamapimod capsules utilized during the double-blind phase and part of the Extension phase (Old Capsules) was associated with plasma exposures below the expected and targeted range, while capsules from a new batch of neflamapimod utilized during the majority of the Extension phase of the trial (New Capsules) were associated with achievement of target plasma concentrations and observation of statistically significant clinical benefit.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When evaluating clinically meaningful disease progression, defined as &#8805;&nbsp;1.5-point increase in CDR-SB, with a Kaplan-Meier time to progression analysis, patients treated with New Capsules demonstrated statistically significant slowed disease progression compared to patients treated with Old Capsules over 32 weeks as summarized in Table 1 below. Even greater risk reductions were observed in patients with ptau181&#8239;&lt;&#8239;2.2&#8239;pg/mL &#8211;&nbsp;the threshold CervoMed believes is the optimal ptau181 threshold for evaluating the presence of AD co&#8209;pathology in patients with DLB.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Table 1. Risk of </i></b>&#8805;<b><i> 1.5-point Increase in CDR-SB at Week 32 of Treatment during RewinD-LB Trial</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 23.8%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b><i>Screening p-tau </i></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23.8%; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b><i>Patients</i></b></p>
			</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;">&nbsp;</td>
			<td colspan="1" id=".amt.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i><b><b><i>Hazard ratio</i></b></b></i></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;">&nbsp;</td>
			<td colspan="1" id=".amt.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i><b><b><i>95% CI</i></b></b></i></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 22.5%; border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b><i>p-value</i></b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>ptau181 &lt; 2.4 pg/mL</i></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>NC=126, OC=117, PBO=79</i></p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 9pt; border-left: 1px solid black;"><i>0.46</i></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 9pt;"><i>0.31-0.70</i></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>p=0.0037</i></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>ptau181 &lt; 2.2 pg/mL</i></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>NC=105, OC=99, PBO=70</i></p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 9pt; border-left: 1px solid black;"><i>0.36</i></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 9pt;"><i>0.23-0.56</i></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>p=0.0001</i></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>ptau181 &lt; 1.8 pg/mL</i></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>NC=74, OC=69, PBO=46</i></p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 9pt; border-left: 1px solid black;"><i>0.35</i></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); padding-left: 9pt;"><i>0.20-0.61</i></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><i>p=0.0002</i></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>NC=New Capsules; OC=Old Capsules; PBO=Placebo</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Researchers also presented data evaluating different cut-off levels of ptau181 in relation to the 32-week results and evaluated the correlation between ptau181 and ptau217, a validated biomarker for AD. Utilizing published cutoffs for plasma ptau217 (0.63 pg/mL) and ptau181 (2.2 pg/mL), there is 92% concordance for presence or absence of AD co-pathology, and a strong correlation of (r=0.81, p&lt;0.001). These findings demonstrate that the established ptau181 cutoff of 2.2 pg/mL for AD also appears to be the optimal cutoff to maximize neflamapimod treatment response. Ptau181 and ptau217 appear to be equally predictive for identifying AD-co-pathology in patients with DLB.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">1</sup>&nbsp;All analyses reported are exploratory in nature, along with 95% confidence intervals. However, p-values and indications of statistically significance are being reported to provide a measure of the probability that any differences identified between the samples are due to chance</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="image1.jpg" src="image1.jpg"></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These new data, including the Kaplan-Meier curves associated with these analyses, are available in a presentation published today under &#8220;Events &amp; Presentations&#8221;&nbsp;in the&nbsp;Investor Relations&nbsp;section of the Company&#8217;s website,&nbsp;https://www.cervomed.com.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>New Data: Reduction in Plasma Levels of Glial Fibrillary Acidic Protein at Week 32 of Extension Phase</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company also announced today that it has completed an analysis of GFAP data from the Extension phase of the RewinD-LB trial.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At Week 32 of the Extension phase, there was a statistically significant reduction (p&lt;0.0001) from baseline (i.e., start of extension) in GFAP plasma levels in patients who received New Capsules for all 32 weeks, with a mean change of -18.4&#177;4.0 pg/mL in all participants (N=107) and -21.2&#177;4.4 pg/mL in participants with screening plasma ptau181 below 2.2 pg/mL (N=91). In contrast, placebo-recipients in the initial, double-blind phase of the trial had a mean increase from baseline to Week 16 of +1.1&#177;3.0 pg/mL in all participants (N=74) and +1.1&#177;3.3 pg/mL in the subset with screening plasma ptau181 below 2.2 pg/mL (N=65).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Previously Presented 16-Week Extension Phase Data</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Improvement on primary outcome measure, change in CDR-SB, with the New Capsules both vs. Old Capsules (p&lt;0.001) during first 16 weeks of the Extension phase and vs. placebo (p=0.003).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The percentage of participants who had clinically meaningful worsening (i.e., an increase greater than or equal to 1.5 points on their CDR-SB score) during the first 16 weeks of the Extension phase of the trial was 40% lower on a relative basis in New Capsule recipients compared to Old Capsule recipients, and 62% lower in participants whose screening plasma ptau181 &lt; 2.2 pg/mL.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statistically significant improvement on Alzheimer&#8217;s Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) in participants administered New Capsules both in comparison to Old Capsules (p=0.035) and in a within-participant comparison to placebo treatment (p=0.039). The improvement compared to placebo in the within-participant analysis was not seen with the Old Capsules.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Full results from the first 16 weeks of the Extension phase can be found here.<br>
			&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Old and New Capsules Have Similar Overall Safety and Tolerability Profile During Extension Phase</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Both Old and New Capsules demonstrated comparable tolerability profiles and no new safety signals were identified during the Extension phase of the trial.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the first 16 weeks of the Extension phase, a lower incidence of falls was seen in participants with screening ptau181 &lt; 2.2 pg/mL who received New Capsules of neflamapimod as compared to participants who received either Old Capsules or placebo (vs. Old Capsules, p=0.025; vs. placebo, p=0.007)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="image1.jpg" src="image1.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Conference Call / Webcast Details</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed will host a conference call and webcast to review these results today, July 28, 2025, at&nbsp;8:00 AM ET. <b>To register for the webcast, please click </b><b>here</b><b>.</b> Participants should dial 1-877-425-9470 (domestic) or 1-201-389-0878&nbsp;(international) with the code 13755139.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To access the Call me&#8482; feature, which avoids having to wait for an operator, click&nbsp;here.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The live webcast and replay will be available&nbsp;under &#8220;Events &amp; Presentations&#8221; in the&nbsp;Investor Relations&nbsp;section of the Company&#8217;s website,&nbsp;https://www.cervomed.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Trial in Dementia with Lewy Bodies</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial phase of RewinD-LB was a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in 159 patients with DLB, followed by a 32-week neflamapimod-only treatment Extension phase. Patients with AD co-pathology, as assessed by plasma ptau181 levels, were excluded from the trial. Compared to patients with &#8220;pure&#8221; DLB &#8211; who may comprise up to 50% of the total diagnosed DLB patient population at any given time &#8211; DLB patients with AD co-pathology have significant, irreversible neuronal loss in the hippocampus that limits response to treatment. The primary endpoint in the trial is change in the CDR-SB, and secondary endpoints include ADCS-CGIC, the Timed Up and Go test, and a cognitive test battery. The RewinD-LB trial is funded primarily by a&nbsp;$21.3 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, which is expected to be disbursed over the course of the trial as costs are incurred. The trial includes 43 sites across in&nbsp;the&nbsp;United States, the&nbsp;United Kingdom, and&nbsp;the&nbsp;Netherlands. Participants completing the 16-week initial portion of the trial were able to continue in an open-label Extension portion of the trial to receive neflamapimod for an additional 32 weeks. The Extension trial protocol includes a pre-specified data readout after the first 16 weeks of the same outcome measures assessed during the placebo-controlled portion of the trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="image1.jpg" src="image1.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic effects; the anticipated timing and achievement of clinical and development milestones, including the Company&#8217;s announcement of additional data, if any, from the RewinD-LB Phase 2b clinical trial and any meeting or correspondence between the Company and the FDA; any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB trial will be replicated in later trials; and the timing of the initiation of any potential future trials or interactions with regulatory authorities, including the Company&#8217;s need to acquire sufficient funding for any Phase 3 trial of neflamapimod in DLB. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media</b><br>
Argot Partners<br>
liza@argotpartners.com&nbsp;<br>
212-600-1902</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crvo-20250728.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2025 3:01:57 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:crvo="http://www.crvo.com/20250728" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crvo.com/20250728">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/cyd-8k-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20250728_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20250728_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20250728_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.crvo.com/20250728/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="crvo_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>crvo-20250728_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2025 3:01:57 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.crvo.com/20250728/role/statement-document-and-entity-information" xlink:href="crvo-20250728.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.crvo.com/20250728/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>crvo-20250728_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2025 3:01:57 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>crvo-20250728_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 7/28/2025 3:01:57 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.crvo.com/20250728/role/statement-document-and-entity-information" xlink:href="crvo-20250728.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.crvo.com/20250728/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !1 0<# 2(  A$! Q$!_\0
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MI/\ CXMX^WRKQQ_SZL>]82J+$TJBMK%N2]'NOR?WFBC[*I%]&K/U6WZGK/\
MP<)_M1ZG\#/V#KCP3X3:27X@_'#48O ^@6\)/G/]I(6X=<<\1$IGL9EKR_\
MX**ZOJ/_  2!_P""+'@3X-_#&8VOCGQ6UCX"TR\MSLE-Y=[GO;I".0[,9=K=
M5,JD?=%&@0_\/*O^#@C4-4;-[\-OV0=,%G;'DP7'B.YSN/INC(;Z&U7UJ_\
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MJTJMM)7NNC3Z"EATZ:A?:UGZ&7X)\5P^.O!^EZU;VVH64&JVL=TEO?VKVMU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">CervoMed Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Jul. 28,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">20 Park Plaza, Suite 424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crvo20250728_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crvo.com/20250728/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvo-20250728.xsd</File>
    <File>crvo-20250728_def.xml</File>
    <File>crvo-20250728_lab.xml</File>
    <File>crvo-20250728_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="crvo20250728_8k.htm">crvo20250728_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvo20250728_8k.htm": {
   "nsprefix": "crvo",
   "nsuri": "http://www.crvo.com/20250728",
   "dts": {
    "schema": {
     "local": [
      "crvo-20250728.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-cr-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "crvo-20250728_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvo-20250728_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvo-20250728_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvo20250728_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 36,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.crvo.com/20250728/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20250728_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20250728_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Axis]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentDomain",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Domain]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r8"
     ]
    },
    "cyd_MaterialCybersecurityIncidentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Table]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.crvo.com/20250728/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-25-023646-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-023646-xbrl.zip
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M!@FAK#863="B(; 1,-5?.ESX[P[&E+/I'41F3Y0Z:B>+%"*[<DPNB2.DTD#
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M8;FZ[&>T2/$B05S#!6^2$4KKL^&%E9-X%%LWRY](]O^IXI?_ %!+ P04
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MP/["R+R$66FY4\WZV)D@;( K;/,-S&H9<"9NIRY#3R0!%[B"NV$S#+ $U[&
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M_6L*N@TA0=X6&02$2B(CYF(,Z1$>$*XD 6T(K"Y^L/J3 ZOHT&?)@CY6[ K
MZ?M)KB=[EA%UT^?[,XR!7,>.9B66ST:JHY-&R0NA<9JDD3!E]M.>PKQ5=T]!
M?/X3/GKIS%=,*.Y2/R6,"J,,N\WFW_4 \,$+MF2XCX*I#L4B$5ZA2!1-F1%R
M$-]0@,K7&QOGV+MG\K6]T"O(_&:E>\!\.@6+>(.X(T[JRKL7-ELO%IME9!UR
MG\$'0R;RF-G"C)5C-;=W6HWOC)J7RVAEU%S0ZZ,D2>=J7EK$TW:EV[0M>ZNU
M:3?OB"CXJ27S=0CHAI8?]/Q#-6:"_!L<;^EQ'1+D;<QSKPLL(<^+^8=7*; ;
MO7 RX5*N&9FH XAA[L?B<4U<>E0;U,YKI#^)_'#&Q#J16509Y"2LK<#I,D4
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M*+*("$'C8W Z#*_)D/GA%*F"C4@[TK:^D)&N121<@D)0+/" 6BH$@DUB7]&
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M#>YVS?X+!K5X8"97@V1*I'2JWH04]\_R59?567FHIET:8VV4#BI-?CW9B)&
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M@2?@A]V=1Z!CTVN15!?%L_T%8 V ;CV&?P E,P/&)L)^/1/&$CX1F2&KDIA
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MH[HX2O]&1DP *[80M$G)*9%2/AF\!3A%ZDVD"CH'0P" F72!*34^]#C5WE0
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M#;C?$>>U5A=O(-$14U OW$ECIX2/L+38PU4?\; JO%?$PMB-959O5LB@[JR
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MC=5^UQBL"T'"7T;&GX/03K,P./Y_4$L! A0#%     @ %('\6JF#6=.! P
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M,#(U,#<R.%]P<F4N>&UL4$L! A0#%     @ %('\6J,'XCX4$P  ^G<  !,
M             ( !D1,  &-R=F\R,#(U,#<R.%\X:RYH=&U02P$"% ,4
M"  4@?Q:[JP!&:(=  "QI0  #0              @ '6)@  97A?.#0T,S<R
:+FAT;5!+!08     !@ & (0!  "C1      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>crvo20250728_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvo-20250728.xsd" xlink:type="simple"/>
    <context id="d20258K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20258K" id="ixv-291">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20258K" id="ixv-292">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20258K" id="ixv-302">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20258K" id="ixv-303">2025-07-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20258K" id="ixv-304">CervoMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20258K" id="ixv-305">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20258K" id="ixv-306">001-37942</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20258K" id="ixv-307">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20258K" id="ixv-308">20 Park Plaza, Suite 424</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20258K" id="ixv-309">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20258K" id="ixv-310">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20258K" id="ixv-311">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20258K" id="ixv-312">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20258K" id="ixv-313">744-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20258K" id="ixv-314">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20258K" id="ixv-315">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20258K" id="ixv-316">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20258K" id="ixv-317">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20258K" id="ixv-318">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20258K" id="ixv-319">CRVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20258K" id="ixv-320">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20258K" id="ixv-321">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
